IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Time to Buy?

IPSEN (OTCMKTS:IPSEY) shares gapped up before the market opened on Wednesday. The stock had previously closed at $40.00, but opened at $42.9960. IPSEN shares last traded at $42.9960, with a volume of 298 shares traded.

Wall Street Analyst Weigh In

IPSEY has been the topic of several recent research reports. HC Wainwright restated a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Finally, Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

IPSEN Trading Up 5.0%

The stock has a 50-day moving average price of $44.46 and a 200 day moving average price of $46.11.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.